Medtronic’s IN.PACT AV Access Postapproval Study Reports 12-Month Outcomes

April 15, 2026—Medtronic announced that 12-month findings from the IN.PACT AV Access postapproval study of the company’s In.Pact AV drug-coated balloon (DCB) demonstrated the device’s safety and effectiveness in the treatment of arteriovenous (AV) fistula stenoses in patients with end-stage renal disease (ESRD) on dialysis.

Ellipsys Vascular Access System to Return to Market

April 2, 2026—Ellipsys Medical, Inc. announced that the Ellipsys vascular access system will re-enter the market, with commercial availability of the device anticipated in mid-2026.

VentureMed Group Is Now Doing Business as Flex Vascular

March 6, 2026—VentureMed Group, Inc. announced it is now doing business as (DBA) Flex Vascular.

Phraxis Begins Postapproval Study of EndoForce Anastomotic Connector

February 4, 2026—Phraxis Inc. announced the initiation of its postapproval study (PAS) for the EndoForce anastomotic connector.

Amplifi Vein Dilation System Gains FDA Breakthrough Device Designation

January 14, 2026—Amplifi Vascular, Inc., a developer of solutions for hemodialysis vascular access, announced it has been granted Breakthrough Device designation from the FDA and Category B assignment from the Centers for Medicare & Medicaid Services for the company’s Amplifi vein dilation system.

Solaris Endovascular’s DEScover Trial Completes Enrollment

January 13, 2026—Solaris Endovascular, Inc. announced that the DEScover clinical trial has completed enrollment.

CorMedix DefenCath Evaluated to Prevent Catheter-Related Bloodstream Infections in Hemodialysis

December 29, 2025—CorMedix Therapeutics announced interim results for the company’s ongoing real-world study of its DefenCath (taurolidine and heparin) to prevent catheter-related bloodstream infections (CRBSI) in adult patients receiving hemodialysis with central venous catheters.

Healionics’ Stargraft Arteriovenous Graft Evaluated in 24-Month Data

November 25, 2025—Healionics Corporation, a developer of synthetic biomaterial-based medical devices, announced recently that 24-month clinical results for its investigational Stargraft arteriovenous (AV) graft were presented by John Ross, MD, at the CiDA, the Controversies in Dialysis Access symposium.

Pathfinder Medical Appoints Dr. Lorenzo Patrone as CMO

November 25, 2025—Pathfinder Medical, a United Kingdom-based developer of minimally invasive vascular access technologies, announced the appointment of Lorenzo Patrone, MD, as the company’s Chief Medical Officer.

CANSCAN Trial Evaluates Semiautonomous Vascular Mapping With Vexev VxWave Imaging System

November 19, 2025—Vexev and U.S. Renal Care announced the results of the CANSCAN feasibility trial, which provided evidence that Vexev’s VxWave ultrasound imaging system can reliably perform semiautonomous vascular mapping examinations directly within the dialysis clinic.

VENOS-3 Pivotal Study Begins for Venova’s Velocity pAVF System

November 6, 2025—Venova Medical announced the enrollment of the first patients in the VENOS-3 pivotal study of the company’s Velocity percutaneous arteriovenous fistulas (pAVF) system.

Efficacy Outcomes From AVG Cohort of WAVE Presented for Merit’s Wrapsody CIE

November 3, 2025—Merit Medical Systems, Inc. announced 24-month efficacy outcomes from the nonrandomized arteriovenous graft (AVG) cohort of the WAVE trial.

Antithrombogenic Indication Cleared for Access Vascular’s HydroMid and HydroPICC

October 22, 2025—Access Vascular, Inc. announced that the FDA cleared a new indication for its single-lumen Mimix HydroMid midline catheter and its single- and dual-lumen HydroPICC peripherally inserted central catheter.

SIR Publishes Practice Guidance on pAVF for Dialysis Access

September 9, 2025—The Society of Interventional Radiology (SIR) announced that a new practice guidance for the creation of percutaneous arteriovenous fistulas (pAVFs) for dialysis access was published by Bart L. Dolmatch, MD, et al in Journal of Vascular and Interventional Radiology.

Venova’s Velocity pAVF System Pivotal Study Receives IDE Approval

August 21, 2025—Venova Medical announced FDA investigational device exemption (IDE) approval to initiate the VENOS-3 pivotal study of the company’s Velocity percutaneous arteriovenous fistula (pAVF) system.

Vascular Access With Merit’s Wrapsody CIE Studied in WRAP North America Registry

August 18, 2025—Merit Medical Systems, Inc. announced that the first patient was enrolled in the company’s WRAP North America registry, which is evaluating the company’s Wrapsody cell-impermeable endoprosthesis (CIE).

CANSCAN Trial of AVF Mapping With VxWave Ultrasound Imaging System Completes Enrollment

July 29, 2025—Vexev and U.S. Renal Care announced the completion of enrollment in the CANSCAN clinical trial, a multicenter feasibility study evaluating the use of semiautonomous ultrasound scanning with Vexev’s VxWave system for arteriovenous fistula (AVF) mapping in dialysis clinics.

Medtronic Focuses on Carotid Therapies, Thrombectomy, and BTK Disease; Exits AVF Creation

June 13, 2025—With a distribution agreement in place and an option to acquire Contego Medical, Medtronic’s peripheral vascular division kicked off 2025 with renewed investment in the carotid artery stenting (CAS) field.

FDA Approves Phraxis EndoForce Connector for Endovascular Venous Anastomosis

May 22, 2025—Phraxis Inc. announced FDA approval of the EndoForce connector for endovascular venous anastomosis for dialysis access in patients with end-stage renal disease.

BD Reports Results from AV Fistula Cohort of Lutonix AV Global Registry

May 21, 2025—BD (Becton, Dickinson and Company) announced post hoc analysis results from the arteriovenous (AV) fistula cohort of the Lutonix Global AV Registry.